The MD&A Has Two Versions. Only One Gets Filed.
A Practical Checklist to Assess Whether Your MD&A Informs Investors or Just Meets Compliance
Indian listed companies are producing longer Management Discussion & Analysis (MD&A) sections than ever before, with more indicators, more commentary, and more regulatory alignment. But longer reports do not always translate into better disclosure quality.
While regulatory compliance continues to improve, disclosure quality often struggles to keep pace. Unlike compliance, quality has no external regulator or formal benchmark.
The MD&A Quality Scorecard helps CFOs, Company Secretaries, and Investor Relations teams assess whether their Management Discussion & Analysis truly informs investors or simply satisfies a regulatory requirement. It provides a structured framework to strengthen forward-looking disclosure, reduce data silos, and bridge the gap between internal boardroom discussions and external reporting.
What’s Inside this Checklist
- Strategy & Narrative Alignment: Shifts your MD&A from boilerplate compliance to true strategic analysis that goes beyond just restating the financials.
- Forward-Looking Risk & Data: Replaces generic risk statements with specific disclosures (like SEBI’s BRSR mandates) and concrete sensitivity analysis.
- Traceability & Audit Governance: Eliminates data contradictions between your annual report, BRSR, and investor decks while securing a clear approval trail.
MD&A Quality Scorecard
Ready to take the next step?
Book a free Consultation with IRIS CARBON® today!